Clinical Trial: A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.

U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07362459) titled 'A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.' on Jan. 09.

Brief Summary: This Phase III, randomized, double-blind study compares the efficacy and safety of SCTB14 versus pembrolizumab as first-line treatment in patients with driver gene-negative, TPS >=10% locally advanced or metastatic non-small cell lung cancer (NSCLC). The primary objective is to assess superiority of SCTB14 over pembrolizumab in prolonging progression-free survival. Safety will be closely monitored.

Study Start Date: Dec. 30, 2025

Study Type: INTERVENTIONAL

Condition: Non-Small Cell Lung Carci...